Short Interest in Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Increases By 37.2%

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 26,200 shares, a growth of 37.2% from the February 13th total of 19,100 shares. Based on an average trading volume of 53,400 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James reaffirmed a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research report on Monday, February 3rd.

Medexus Pharmaceuticals Stock Down 1.1 %

MEDXF stock traded down $0.02 on Monday, reaching $1.77. 3,575 shares of the company traded hands, compared to its average volume of 39,077. Medexus Pharmaceuticals has a one year low of $1.08 and a one year high of $3.88. The firm has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $2.06.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.